Kairos Pharma Reports Q2 2026 Financial Results with Net Loss of $1.388 Million

Kairos Pharma, Ltd. reported its financial results for the second quarter of 2026, revealing a net loss of $1.388 million, a slight decrease from the $1.422 million loss recorded in the same period of 2025. For the first half of 2026, the company reported a net loss of $3.042 million, compared to a loss of $2.684 million in the first half of 2025. The company has not generated any revenue during these periods, maintaining its status as a clinical-stage biopharmaceutical firm focused on developing immunotherapy and cell therapy treatments for oncology.

Operating expenses for the second quarter of 2026 totaled $1.417 million, down from $1.456 million in the prior year. Research and development expenses were $619,000 for the quarter, an increase from $496,000 in the same quarter of 2025, primarily due to costs associated with ongoing clinical trials. General and administrative expenses decreased to $798,000 from $960,000 year-over-year, reflecting a reduction in certain operational costs. For the first half of 2026, total operating expenses rose to $3.107 million from $2.722 million in the previous year, driven by increased research and development activities.

As of June 30, 2026, Kairos Pharma reported total assets of $4.456 million, a decline from $6.540 million at the end of 2025. The company's cash and cash equivalents decreased to $2.626 million from $4.491 million, raising concerns about its liquidity and ability to fund ongoing operations. The company has experienced recurring losses since its inception, leading to an accumulated deficit of $17.304 million as of the end of the reporting period. The company’s independent auditors have expressed substantial doubt about its ability to continue as a going concern, emphasizing the need for additional funding.

In terms of strategic developments, Kairos Pharma raised $392,000 through an At the Market (ATM) offering during the first half of 2026, selling 601,947 shares of common stock. Subsequent to the reporting period, the company raised an additional $911,000 through the sale of 2,359,326 shares under the same ATM offering. The company is also engaged in various agreements to support its clinical trials, including a Pharmaceutical Development Services Agreement with Brammer Bio MA, LLC, which involves the manufacturing of clinical supplies for its ENV-105 product.

Looking ahead, Kairos Pharma anticipates continued increases in operating expenses as it advances its clinical trials and seeks regulatory approvals for its product candidates. The company plans to finance its operations through a combination of equity offerings, debt financing, and potential collaborations. However, it acknowledges the uncertainty surrounding its ability to raise additional funds and the potential impact on its business operations if it fails to secure necessary financing.